Website

Stereotaxis Inc. (STXS) is a Biotechnology: Electromedical & Electrotherapeutic Apparatus company listed on AMEX. In the last 30 days Quantisnow tracked 7 wire items for STXS, including 4 press releases and news items, 2 earnings updates and 1 SEC filing. The most recent was published Nov 10, 2026.

Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.

STXS rankings

Financial highlights

Full financials
Revenue, TTM
$30.07M
Revenue growth
-5.5%
Net income, TTM
-$22.32M
Net margin
-74.2%
Free cash flow, TTM
-$15.50M
Cash
$10.49M

For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks31+100%
2026-05-17: 02026-05-24: 12026-05-31: 02026-06-07: 02026-06-14: 02026-06-21: 02026-06-28: 62026-07-05: 22026-07-12: 32026-07-19: 22026-07-26: 02026-08-02: 12026-08-09: 72026-08-16: 02026-08-23: 02026-08-30: 12026-09-06: 02026-09-13: 12026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 22026-10-25: 12026-11-01: 12026-11-08: 3
2026-05-172026-11-08
Mix1390d
  • SEC Filings5(38%)
  • Other5(38%)
  • Earnings2(15%)
  • Leadership1(8%)
Activity · 52 weeks6137 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

STXS FAQ

10 questions
  • What does Stereotaxis Inc. do?
    Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage...
  • What is the latest news on STXS?
    In the last 30 days Quantisnow tracked 7 wire items for STXS: 4 press releases and news items, 2 earnings updates and 1 SEC filing. The most recent was published on November 10, 2026.
  • What is STXS revenue?
    Stereotaxis Inc. (STXS) reported $30.07M of revenue for the twelve months ended Jun 30, 2026. That is down 5.5% from the year before. Revenue for fiscal 2025 was $32.38M.
  • Is STXS profitable?
    No. Stereotaxis Inc. reported a net loss of $22.32M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does STXS have?
    Stereotaxis Inc. reported $10.49M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does STXS stock trade?
    Stereotaxis Inc. (STXS) is listed on AMEX.
  • What sector and industry is STXS in?
    Stereotaxis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.
  • What are analysts saying about STXS?
    Stereotaxis Inc. has had 6 recent analyst actions on file. The most recent action was from Citizens JMP: Mkt Outperform with a $4.00 price target on 2025-12-16. Recent price targets range from $4.00 to $13.00.
  • What companies are similar to STXS?
    Notable peers in the same industry include INMD (InMode Ltd.), AXGN (Axogen Inc.), TMDX (TransMedics Group Inc.), MDT (Medtronic plc.), LIVN (LivaNova PLC). Compare STXS side-by-side with any of them on Quantisnow.
  • How can I track STXS on Quantisnow?
    Quantisnow aggregates Stereotaxis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STXS to receive live email and push alerts on every new disclosure.